VENLO (dpa-AFX) - Qiagen NV (QGEN) said Tuesday that it has launched 14 new GeneRead DNAseq V2 gene panels targeting an extensive range of cancer-related genes or gene regions.
Gene panels are an integral part of many next-generation sequencing workflows. They are used to enrich genes of interest in a sample prior to sequencing runs and as such can be seen as the core assay in the workflow.
Qiagen's new GeneRead panels are customizable to include other genes or gene regions of clinical or biological interest and are compatible with any NGS sequencer. They are part of the company's industry-leading sample-to-library workflows, which are helping to drive the growing use of NGS in clinical applications.
The 14 new GeneRead DNAseq V2 panels cover an extensive range of cancer-related genes and gene regions, including 'focused' panels each targeting 8-25 genes, 'disease-specific' panels for 40-50 genes, and 'comprehensive' panels for as many as 160 genes.
Copyright RTT News/dpa-AFX
© 2014 AFX News
